Chiasma hopes to be able to file its oral acromegaly therapy by year-end, and Novartis wants to shore up its MS franchise.
Shares in generics firms tumble in the wake of a huge lawsuit in the US alleging industry-wide price fixing, signalling many more years of pain for this sector.
Novartis will need to boost Xiidra sales to justify the hefty price it has paid, but the Swiss company has form.
A slew of data on spinal muscular atrophy projects over the weekend shows that this tiny market is set for some big competition, with Novartis, Roche and Biogen jostling…
Alder hopes soon to launch its migraine drug eptinezumab, and will nervously have been watching the first full quarter’s sales of three similarly acting drugs.
The small-molecule oncology player zeroes in on its first commercial opportunity.
Using EvaluatePharma data, Vantage has described how big pharma R&D spending has shifted, showed how internally discovered novel medicines account for a growing…
Tocagen could soar or sink on interim brain cancer data, while judgement day approaches for Syndax.
After completing a phase I study Astrazeneca discontinues development of the Ionis-partnered AZD4785.